Therapeutic Area Clinical Intelligence: Type Type-2 Diabetes Pipeline, Volume 1

Table of Contents

• Scope of Research & Analysis
• Type-2 Diabetes Disease Overview
• Overview of Progression to Type 2 Diabetes
• Global Projections for the Diabetes Epidemic: 2003-2025
• Epidemiology of T2 Diabetes: Current and predicted prevalence
• Currently Available Treatments for T2 Diabetes
• Unmet Need in Type-2 Diabetes Market
• FDA Summary Guidance for Development of T2 Diabetes Therapeutics
• Overview of Competitive Landscape: Late-Stage Products Profiled in Intelligence Report
• Overview of Competitive Landscape: Mid & Early Stage Products Profiled in Intelligence Report
• Competitive Launch Timeline Analysis
• Overview of Clinical Trials Landscape

• Actos Product Overview - Competitor Snapshot
• Avandia Product Overview - Competitor Snapshot
• Byetta Product Overview - Competitor Snapshot
• Januvia Product Overview - Competitor Snapshot
• Symlin Product Overview - Competitor Snapshot
• Galvus Product Overview - Competitor Snapshot

• Alogliptin (SYR-322)
• Alogliptin Product Overview - Competitor Snapshot
• Alogliptin Phase II Study Design & Results
• Alogliptin Phase III Study Design (Ongoing)
• Alogliptin Phase III Study Design (Ongoing)
• Alogliptin Phase III Study Design (Ongoing)
• Alogliptin Phase III Study Design (Ongoing)
• Alogliptin Phase III Study Design & Results
• Alogliptin Phase III Study Design (Ongoing)
• Alogliptin Phase III Study Design (Ongoing)

• Liraglutide
• Liraglutide Product Overview - Competitor Snapshot
• Liraglutide Phase II Study Design & Results
• Liraglutide Phase II Study Design & Results
• Overview of Liraglutide Registrational Program
• Liraglutide Phase III Study Design & Results LEAD 1
• Liraglutide Phase III Study Design (Ongoing) LEAD 2
• Liraglutide Phase III Study Design & Results LEAD 3
• Liraglutide Phase III Study Design (Ongoing) LEAD 4
• Liraglutide Phase III Study Design (Ongoing) LEAD 5
• Liraglutide Phase III Study Design & Results LEAD 6
• Liraglutide Phase III Study Design (Ongoing) Japan NDA-Enabling Trial

• Saxagliptin
• Saxagliptin Product Overview - Competitor Snapshot
• Saxagliptin Phase I Studies (#1 & #2): Design & Results
• Saxagliptin Phase III Study Design & Results
• Saxagliptin Phase III Study Design
• Saxagliptin Phase III Study Design
• Saxagliptin Phase III Study Design & Results
• Saxagliptin Phase III Study Design (Ongoing)
• Saxagliptin Phase III Study Design (Ongoing)

• AGI-1067
• AGI-1067 Product Overview - Competitor Snapshot
• AGI-1067 Phase III Study Design & Interim Results (Ongoing) ANDES (AGI-1067 as a Novel Antidiabetic Agent Evaluation Study)

• Exanatide LAR (exenatide)
• Exenatide LAR Product Overview - Competitor Snapshot
• Exenatide LAR Phase II Study Design & Results
• Exenatide LAR Phase II Study Design (Ongoing)
• Exenatide LAR Phase III Study Design & Results-DURATION-1
• Exenatide LAR Phase III Study Design (Ongoing)
• Exenatide LAR Phase III Study Design (Ongoing)
• Exenatide LAR Phase III Study Designs (Ongoing)

• Dapagliflozin
• Dapagliflozin Product Overview - Competitor Snapshot
• Dapagliflozin Phase II Study Design & Results
• Overview of Dapagliflozin Registrational Program
• Dapagliflozin Phase III Study Design (Ongoing)
• Dapagliflozin Phase III Study Design (Ongoing)
• Dapagliflozin Phase III Study Design (Ongoing)
• Dapagliflozin Phase III Study Design (Ongoing)

• Balaglitazone
• Balaglitazone Product Overview - Competitor Snapshot
• Balaglitazone Phase II Study Design & Results
• Balaglitazone Phase III Study Design (Ongoing)

• BI-1356
• BI-1356 Product Overview - Competitor Snapshot
• BI-1356 Phase I/II Study Design & Results
• BI-1356 Phase I/II Study Design & Results
• BI-1356 Phase I/II Study Design (ongoing)
• BI-1356 Phase III Study Design (Ongoing)
• BI-1356 Phase III Study Design (Ongoing)
• BI-1356 Phase III Study Design (Ongoing)
• BI-1356 Phase III Study Design (Ongoing)
• BI-1356 Phase III Study Design (Ongoing)

• rivoglitazone (CS-011)
• rivoglitazone Product Overview - Competitor Snapshot
• Rivoglitazone Phase II/III Study Design & Results
• Rivoglitazone Phase III Study Design (Ongoing)

• AVE-0010
• AVE-0010 Product Overview - Competitor Snapshot
• AVE-0010 Phase IIa Study Design & Results
• AVE-0010 Phase IIb Study Design
• AVE-0010 Phase 2b Top-Line Efficacy Results
• AVE-0010 Product Positioning

• R1583
• R1583 Product Overview - Competitor Snapshot
• R1583 Phase II Study Design & Results
• R1583 Phase II Study Design & Results
• R1583 Phase II Study Design & Results
• R1583 Phase II Study Design & Results

• AVE-2268
• AVE-2268 FDC Product Overview - Competitor Snapshot
• AVE-2268 Phase IIb Study Design
• remogliflozin
• Remogliflozin Product Overview - Competitor Snapshot
• Remogliflozin Phase I Study Design (Ongoing)
• Remogliflozin Phase I Study Design (Ongoing)
• Remogliflozin Phase II Study Design (Ongoing)
• Remogliflozin Phase II Study Design (Ongoing)
• Remogliflozin Phase II Study Design (Completed)

• PHX1149
• PHX1149 Product Overview - Competitor Snapshot
• PHX1149 Phase I Study Design & Results
• PHX1149 Phase I Study Design & Results
• PHX1149 Phase IIa Study Design & Results
• PHX1149 Phase IIb Study Design (Ongoing)

• INT131
• INT131 Product Overview - Competitor Snapshot
• INT131 Phase I Study Design & Results
• INT131 Phase I Study Design & Results
• INT131 Phase IIa Study Design & Results
• INT131 Phase IIb Study Design (Ongoing)

• albiglutide
• albiglutide Product Overview - Competitor Snapshot
• albiglutide Phase I Study Design
• albiglutide Phase I Study Design
• albiglutide Phase I/II Study Design (Ongoing)
• albiglutide Phase IIb Study Design (Ongoing)

• Aleglitazar
• Aleglitazar Product Overview - Competitor Snapshot
• Aleglitazar Phase IIb Study Design (Ongoing)
• Aleglitazar Phase IIb Study Design (Ongoing)

• PF-00734200
• PF-00734200 Product Overview - Competitor Snapshot
• PF-00734200 Phase IIa Study Design & Results
• PF-00734200 Phase IIa Study Design (Ongoing)
• PF-00734200 Phase II Study Design (Ongoing)

• R1579
• R1579 Product Overview - Competitor Snapshot
• R1579 Phase I Study Design & Results
• R1579 Phase II Study Design (Ongoing)

• TAK-472 (SYR-472)
• TAK-472 Product Overview - Competitor Snapshot
• TAK-472 Phase II Study Design (Ongoing)

• AMG-222 (ALS 2-0426)
• AMG-222 Product Overview - Competitor Snapshot

• INCB13739
• INCB13739 Product Overview - Competitor Snapshot
• INCB13739 Phase I Study Design & Results
• INCB13739 Phase IIa Study Design & Results

• MB07803
• MB07803 Product Overview - Competitor Snapshot
• MB07803 Phase IIa Study Design & Results

• ISIS 113715
• ISIS 113715 Product Overview - Competitor Snapshot
• ISIS 113715 Phase I Study Design & Results
• ISIS 113715 Phase II Study Design & Results
• ISIS 113715 Phase II Study Design (Ongoing)

• AZD2207
• AZD2207 Product Overview - Competitor Snapshot

• DIO-902
• DIO-902 Product Overview - Competitor Snapshot
• DIO-902 Phase IIa Study Design & Results
• DIO-902 Phase II/III Study Design (Ongoing)
• DIO-902 Phase II/III Extension Study Design (Ongoing)

• EMD 387008
• EMD 387008 Product Overview - Competitor Snapshot

• indeglitazar
• indeglitazar Product Overview - Competitor Snapshot
• indeglitazar Phase IIa Study Design & Results

• azilsartan
• azilsartan Product Overview - Competitor Snapshot

• MBX-2044
• MBX-2044 Product Overview - Competitor Snapshot
• MBX-2044 Phase IIa Study Design & Results

• CJC-1134-PC
• CJC-1134-PC Product Overview - Competitor Snapshot
• CJC-1134-PC Phase I/II Study Design & Results
• CJC-1134-PC Phase I/II Study Design & Results
• CJC-1134-PC Phase II Study Design (Ongoing)
• CJC-1134-PC Phase II Study Design (Ongoing)

• CRx-401
• CRx-401 Product Overview - Competitor Snapshot
• CRx-401 Phase II Study Design (Ongoing)

• K-111
• K-111 Product Overview - Competitor Snapshot
• K-111 Phase IIa Study Design & Results
• K-111 Phase IIa Study Design & Results

• MP-513
• MP-513 Product Overview - Competitor Snapshot
• MP-513 Phase II Study Design (Ongoing)

• AKP-020
• AKP-020 Product Overview - Competitor Snapshot
• AKP-020 Phase II Study Design (Discontinued)

• AVE0847
• AVE0847 Product Overview - Competitor Snapshot
• AVE0847 Phase II Study Design (Completed-Results Unpublished)

• Disclaimer
• Report Licensing